about
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyMolecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.Use of physician services during the survivorship phase: a multi-province study of women diagnosed with breast cancer.A population-based assessment of primary care visits during adjuvant chemotherapy for breast cancer.Multigene expression profile testing in breast cancer: is there a role for family physicians?Care and Outcomes of Patients With Cancer Admitted to the Hospital on Weekends and Holidays: A Retrospective Cohort Study.Relationships between authorship contributions and authors' industry financial ties among oncology clinical trials.Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.Involvement of low- and middle-income countries in randomized controlled trial publications in oncologyEffectiveness of specialized palliative care: a systematic review.Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasmsA systematic review of factors influencing older adults' decision to accept or decline cancer treatment.Sociodemographic factors associated with cervical cancer screening and follow-up of abnormal results.American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across ContinentsIn vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.Models that work: incorporating quality principles in different clinical settingsAssociation of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort studyOncologists' strategies and barriers to effective communication about the end of life.Perceptions of palliative care among patients with advanced cancer and their caregiversEvolution of the randomized controlled trial in oncology over three decades.Approach to fever assessment in ambulatory cancer patients receiving chemotherapy: a clinical practice guideline.Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid CancerDevelopment of a patient registry to evaluate hospital admissions related to chemotherapy toxicity in a community cancer center.Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elementsTime to get serious about improving the safety of oral chemotherapyEnd of life care for women with gynecologic cancers.Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review.Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice.Identifying population-level indicators to measure the quality of cancer care for women.How may clinical research improve healthcare outcomes?Quality of clinical trials in gastroenteropancreatic neuroendocrine tumours.High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit.Oral chemotherapy practices at Ontario cancer centres.Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis.Managing skin toxicities related to panitumumab.A Decade of Research on the Quality of Systemic Cancer Therapy in Routine Care: What Aspects of Quality Are We Measuring?My Team of Care Study: A Pilot Randomized Controlled Trial of a Web-Based Communication Tool for Collaborative Care in Patients With Advanced CancerA randomized phase II trial of geriatric assessment and management for older cancer patients.Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial.
P50
Q28545130-9C4AD6A6-16D8-4343-BECC-CCB014DD142CQ30826387-C16529BE-D470-48EC-A627-0AA0AC8714D7Q33611113-29F41ED4-6AB1-4129-91AE-799ADFDD355FQ33611119-44CBC228-0F84-4ED1-B059-6A2F8458ADA6Q33611126-580CE8CB-1867-4F9C-9673-70A08A7F873BQ34533961-2D2A132A-C353-44E4-8CAF-C512E1874098Q34578579-A10061A4-0879-4EC6-92A9-D390C7EB6F17Q34661188-3CE1088B-4091-467E-AE56-678E3390A4D2Q34752022-5A840395-38BC-4742-AEEE-499C1E25E300Q34768703-F6D21958-6E9D-46D9-B673-34DD6185D5A5Q35445073-12362BF4-F1B0-4DFD-9451-58F77FF221ABQ35541354-9958B850-75AC-4616-BD8D-9F61E38E2720Q35688714-6084BC6F-B373-4753-8F5D-D1BF305E5A6BQ35806164-F46F88FD-4D86-4CF6-908F-617260431DE9Q36673445-D82D3E16-E1E1-4D26-BF89-2A9C1861140FQ36747337-A1F92FDC-93EE-4D73-8218-FE29F0EE7B87Q36835922-A4639951-15E2-4940-98D9-39C26D654479Q36900970-9051F363-B5C8-4974-8B5C-CD3119207476Q37008546-1707FCA0-0C1A-44B2-B3C8-DFF91268174AQ37079647-DEE5C28A-5B3C-4DC3-BDDF-A047CD01788EQ37117089-79B9F6C4-43CD-47E4-BF7C-DAA1C8EA0C78Q37152897-48F3B51C-BCC6-4616-A779-4C2248A77C86Q37393234-1B883276-51AC-47D0-B14D-1FFC1DECC563Q37476002-812C9F4C-FF90-41A0-BA8D-416DD411E9E8Q37505185-131A642D-6286-4BD8-B65E-466808B27001Q37671186-797A3E43-A9D8-43EF-9751-16747F9B6F9DQ37751432-C1EDE442-FEA3-4339-8732-43C95D192F26Q37811673-0D0E7276-2386-48B3-B752-1263B5CB6E24Q37900076-FF83A1DA-AEA6-4758-8E4B-839A8D7CFACAQ37906058-917A7680-EF0D-4711-B824-A08F2BF5BD1EQ37950989-C069E9F1-1923-4D87-8435-10A2DD7866C5Q37993338-2D11E1AF-F46D-4072-9D8A-DF238D4A6287Q38189254-DF4B114F-6FDD-4A04-8BA8-17CB7C69D3ABQ38203133-8939828C-998C-478B-92DB-2AEB5D0B8E75Q38233355-F40A2A95-A2A2-4774-BE98-957544CE3DA2Q38236154-A27612A8-4513-4834-97DA-E5D2DCD98D0AQ38285783-81FA3AD6-D17D-447D-A56B-4E045BBF2DF6Q38373060-86C2B2C6-4826-4D99-BBC0-5FCCB3DF5DC5Q38373372-CD0206AB-987B-4C44-B182-771088EE05BFQ38386987-EA280070-9D85-4296-82DF-070BF133326C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Monika K Krzyzanowska
@ast
Monika K Krzyzanowska
@en
Monika K Krzyzanowska
@es
Monika K Krzyzanowska
@nl
Monika K Krzyzanowska
@sl
type
label
Monika K Krzyzanowska
@ast
Monika K Krzyzanowska
@en
Monika K Krzyzanowska
@es
Monika K Krzyzanowska
@nl
Monika K Krzyzanowska
@sl
prefLabel
Monika K Krzyzanowska
@ast
Monika K Krzyzanowska
@en
Monika K Krzyzanowska
@es
Monika K Krzyzanowska
@nl
Monika K Krzyzanowska
@sl
P106
P21
P31
P496
0000-0001-5533-7418